A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Pfizer (PFE) stock in focus as Sally Susman, the company's Chief Corporate Affairs Officer, plans to depart after 18 years.

One of the best known communications executives in corporate America, Susman worked at Pfizer for nearly two decades after ...

Changing market conditions and consumer tastes and preferences have weighed on these businesses. Investors can learn a lot ...

According to Bloomberg, citing an email sent by Chief Executive Officer Albert Bourla on Tuesday, Susman’s responsibilities ...

Pfizer chief corporate affairs officer Sally Susman is departing the company after roughly two decades, CEO Albert Bourla ...

Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Achieve Life Sciences has signed up Omnicom to support the launch of nicotine dependence treatment cytisinicline, positioning ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

The firm’s rapid rise represents a burgeoning American health trend. Between 2019 and 2024 prescriptions for testosterone ...

Taiho Pharmaceutical’s investigational Duchenne muscular dystrophy (DMD) therapy, pizuglanstat, has shown no benefit in a Phase III trial.

Ahead of the vote on Thursday, Ursula von der Leyen, president of the commission, appeared before the European Parliament to ...